{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/6biiwjswhlw",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1038/ncomms14207",
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.1234/example"
  ],
  "dcterms:references": [
    "# Noradrenergic Regulation of DOPAL-Mediated Aβ Oligomerization Inhibition: A Compensatory Mechanism in Early Alzheimer's Disease\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde) is a reactive intermediate metabolite produced during dopamine oxidation by monoamine oxidase (MAO) that surprisingly exhibits protective effects by decreasing Aβ oligomerization in human neuroblastoma cells, thereby reducing Aβ cytotoxicity. In Alzheimer's disease mouse models like Tg2576, selective loss of dopaminergic neurons occurs in the ventral tegmental area (VTA) during pre-plaque stages, reducing dopamine release in the hippocampus and impairing synaptic plasticity. Interestingly, noradrenaline outflow in the hippocampus remains unchanged in young Tg2576 mice, indicating preserved noradrenergic projections from the locus coeruleus (LC) during early disease stages.\n\n## 2. Knowledge Gap\nDespite evidence that both dopamine metabolism (generating DOPAL) and noradrenergic systems influence Aβ pathology, the potential regulatory relationship between preserved noradrenergic function and DOPAL-mediated inhibition of Aβ oligomerization remains unexplored. Specifically, it is unknown whether noradrenergic signaling modulates the production or efficacy of DOPAL as a compensatory mechanism to counteract diminishing dopaminergic input in early Alzheimer's disease.\n\n## 3. Central Hypothesis\nPreserved noradrenergic signaling in early Alzheimer's disease promotes region-specific DOPAL production through adrenergic receptor-mediated regulation of monoamine oxidase activity, creating a compensatory anti-amyloidogenic mechanism that maintains DOPAL's inhibitory effect on Aβ oligomerization despite declining dopaminergic function.\n\n## 4. Proposed Mechanism\n1. Noradrenaline from preserved LC projections activates α2-adrenergic receptors on remaining dopaminergic terminals in the hippocampus, enhancing presynaptic dopamine release through disinhibition of voltage-gated calcium channels.\n2. Simultaneously, noradrenaline activates β1-adrenergic receptors on astrocytes and microglia, which selectively upregulates MAO-B expression through cAMP/PKA/CREB signaling pathways.\n3. The combination of enhanced dopamine release and increased MAO-B activity creates optimal localized production of DOPAL within affected brain regions.\n4. DOPAL binds to specific hydrophobic regions of Aβ monomers that are critical for β-sheet formation, creating DOPAL-Aβ adducts that prevent oligomerization through steric hindrance.\n5. This noradrenergic-dependent DOPAL production maintains a balance that favors monomeric Aβ, which is more readily cleared by NEP and ADAM17 (as observed with L-DOPA treatment in 5xFAD mice), reducing the formation of toxic oligomers and subsequent plaque development.\n\n## 5. Testable Predictions\n1. Pharmacological antagonism of α2- and β1-adrenergic receptors in young Tg2576 mice should reduce hippocampal DOPAL levels, increase Aβ oligomerization, and accelerate cognitive decline compared to untreated controls.\n2. Chemical ablation of LC noradrenergic neurons (using DSP-4) in pre-plaque Tg2576 mice should decrease hippocampal DOPAL/dopamine ratios and increase Aβ oligomer formation, effects that could be rescued by direct application of synthetic DOPAL.\n3. Post-mortem analysis of human AD brains should reveal a negative correlation between LC neuronal integrity, hippocampal DOPAL levels, and Aβ oligomer concentration in early Braak stages, with this relationship disappearing in advanced disease.\n\n## 6. Potential Experimental Approaches\n1. Develop an ex vivo system using acute hippocampal slices from Tg2576 mice to simultaneously measure noradrenaline, dopamine, DOPAL, and Aβ oligomerization in real-time using microdialysis coupled with LC-MS/MS and ELISA. Manipulate the system with adrenergic receptor agonists/antagonists and MAO-B inhibitors to observe the dynamic relationships between these factors.\n\n2. Generate a transgenic mouse model with fluorescent reporters for MAO-B expression and Aβ oligomerization, combined with chemogenetic control of LC noradrenergic neurons. This would allow for longitudinal in vivo imaging to monitor how manipulating noradrenergic activity affects MAO-B expression, DOPAL production, and Aβ oligomerization in real-time during disease progression.\n\nThis hypothesis suggests a novel homeostatic mechanism whereby preserved noradrenergic function compensates for early dopaminergic deficits by optimizing DOPAL production to counteract Aβ oligomerization. This model explains why noradrenergic preservation in early AD might be neuroprotective and offers new therapeutic avenues targeting the noradrenergic-DOPAL-Aβ axis before significant neurodegeneration occurs."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "biochemical pathways"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "Noradrenaline outflow in the hippocampus did not differ between wild-type and Tg2576 mice at 6 months of age, suggesting preserved noradrenergic projections from the locus coeruleus."
  ],
  "dcterms:abstract": [
    "The study examines dopaminergic neuron loss in Alzheimers disease focusing on the ventral tegmental area VTA in Tg2576 mice The research demonstrates selective loss of dopaminergic neurons specifically in the VTA during pre plaque stages contrasting with Parkinsons disease where neurons are lost in the substantia nigra pars compacta but preserved in VTA Apoptotic cell death contributes to VTA dopaminergic neuron degeneration affecting dopamine release in the hippocampus and impacting synaptic plasticity particularly in the hippocampal CA1 region Reduced dopamine outflow in Tg2576 mice leads to memory deficits and impaired reward processing while noradrenaline outflow remains unchanged indicating preserved noradrenergic projections from the locus coeruleus The study investigated several treatments Levodopa L DOPA administration successfully rescued multiple deficits including CA1 synaptic plasticity dendritic spine density hippocampal post synaptic density composition memory function and food reward processing L DOPA was administered at 10 mg kg along with benserazide at 12 mg kg Similarly selegiline a monoamine oxidase B inhibitor improved dopamine outflow in the hippocampus restored synaptic plasticity dendritic spine density memory performance and reward processing The treatment also restored D1 receptors and GluA1 expression in hippocampal PSD fractions These findings establish a clear link between dopamine signaling memory formation and reward processing in Alzheimers disease with dopaminergic dysfunction occurring at early stages The research suggests potential therapeutic approaches through dopamine system modulation using established drugs like L DOPA and selegiline",
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "Background: Pseudoexfoliation syndrome (PEX) is a common age-related ocular condition characterized by the accumulation of a fibrillar, pseudoexfoliative material on the anterior segment of the eye. This study aims to investigate the histopathological characteristics of pseudoexfoliative material within different ocular structures. Methods: A total of 32 anterior lens capsules, 3 eyelid fragments, and 12 conjunctival specimens were obtained from patients clinically diagnosed with PEX during ocular surgeries. Results: PEX material, characterized by its fibrillar components, is consistently present across multiple ocular structures. The presence of fibrillar eosinophilic deposits across these structures highlights the systemic distribution of PEX material. Conclusions: The involvement of the eyelid and conjunctiva plays a crucial role in understanding PEX pathophysiology.",
    "Movement disorders (MD) have been linked to degeneration of the substantia nigra (SN) in Parkinson’s disease and include bradykinesia, rigidity, and tremor. They are also present in frontotemporal dementia (FTD), where MD have been linked to frontotemporal lobar degeneration with tau pathology (FTLD-tau). The aims of this study are to characterize the frequency and the nature of MD in a cohort of FTLD-TDP brain donors and to investigate the relationship between the presence of MD, the nigral neuronal loss, and the TDP-43 burden in the SN.",
    "This study investigates the relationship between degeneration/regeneration and tubular aggregates (TA) in aged murine models, revealing that TA formation occurs during muscle degeneration but does not correlate with functional improvement.",
    "Heteroplasmy occurs when wild-type and mutant mitochondrial DNA (mtDNA) molecules coexist in single cells. We investigate the dynamics of heteroplasmy in dividing cells and demonstrate that selection acts at the level of cell fitness, influencing the maintenance and purging of nonsynonymous and synonymous mtDNA variants depending on environmental conditions.",
    "Fibrogenesis is part of a normal protective response to tissue injury that can become irreversible and progressive, leading to fatal diseases. Senescent cells are a main driver of fibrotic diseases through their secretome, known as the senescence-associated secretory phenotype (SASP). Here, we report that cellular senescence, and multiple types of fibrotic diseases in mice and humans are characterized by the accumulation of iron...",
    "Age-related decline in mobility and cognition are associated with cellular senescence and NAD + depletion in dogs and people. A combination of a novel NAD + precursor and senolytic, LY-D6/2, was examined in this randomized controlled trial. Seventy dogs with mild to moderate cognitive impairment were enrolled and allocated into placebo, low or full dose groups. Primary outcomes were change in cognitive impairment measured with the owner-reported Canine Cognitive Dysfunction Rating (CCDR) scale and change in activity measured with physical activity monitors.",
    "Alzheimer's disease is a neurodegenerative disorder characterized pathologically by amyloid-beta plaques, tau tangles, and neuronal loss. Our study investigates the role of CSF 14-3-3β in cognitive decline in Alzheimer's disease by analyzing data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). We found that higher CSF 14-3-3β levels correlate with cognitive impairment and other Alzheimer's disease biomarkers, indicating its potential as a diagnostic tool."
  ]
}